{"id":5855,"date":"2020-03-27T09:24:38","date_gmt":"2020-03-27T09:24:38","guid":{"rendered":"http:\/\/www.caltagmedsystems.co.uk\/information\/?p=5855"},"modified":"2020-03-31T14:52:00","modified_gmt":"2020-03-31T14:52:00","slug":"screening-for-covid-19-t-cell-peptides-and-immune-monitoring-with-mhc-tetramers-in-a-single-assay","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/screening-for-covid-19-t-cell-peptides-and-immune-monitoring-with-mhc-tetramers-in-a-single-assay\/","title":{"rendered":"Screening for COVID-19 T-Cell Peptides and Immune Monitoring with MHC Tetramers In A Single Assay"},"content":{"rendered":"<p><a href=\"https:\/\/www.caltagmedsystems.co.uk\/pricing_ordering\/search_results.php?searchtype=all&amp;searchwords=covid-19\">COVID-19<\/a> infected cells can be recognized by T-cells only after SARS-CoV-2 peptides are processed and presented in the context of self MHCs.<\/p>\n<p>Identifying these peptides have essential utilities:<\/p>\n<ul>\n<li>Immune monitoring: Using peptide-MHC tetramers to assess vaccine-induced immunity<\/li>\n<li>Designing potent vaccines that elicit durable responses<\/li>\n<\/ul>\n<p>T-cells are activated only by interacting with processed peptides (e.g. of SARS-CoV-2) that sit in the groove of MHC Class I and II molecules. Identifying these peptides can be used (in forms of peptide-MHC tetramers) to assess vaccine induced immunity and assist in designing potent vaccines with durable responses.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter\" src=\"https:\/\/blog.mblintl.com\/hs-fs\/hubfs\/shutterstock_1626588280-1.jpg?width=534&amp;name=shutterstock_1626588280-1.jpg\" alt=\"shutterstock_1626588280-1\" width=\"688\" height=\"386\" \/><\/p>\n<p><a href=\"https:\/\/www.caltagmedsystems.co.uk\/mbl\/\">MBL International<\/a> can assist companies and academic investigators who are actively developing coronavirus vaccines with our unique QuickSwitch&#x2122; custom tetramer platform.\u00a0 QuickSwitch&#x2122; is a peptide screening plug and play platform that identifies peptides that are more likely to be immunogenic and yet generates corresponding Class I and Class II MHC tetramers.\u00a0 These platforms can identify and validate multi-epitope candidates of SARS-CoV-2 proteins that can potentially elicit for both CD4+ and CD8+ T-cell immune responses. In fact, the QuickSwitch&#x2122; custom tetramer kit has been used in peer-reviewed journals by Stephen J. Elledge and Steven A. Rosenberg teams\u00a0<sup>1,2<\/sup>.<\/p>\n<p>Briefly, the protein sequence of SARS-CoV-2 is known and the predicted epitopes are identified and available published\/reviewed by recent articles including one by Dr. Alex Sette:<\/p>\n<p><a href=\"https:\/\/marlin-prod.literatumonline.com\/pb-assets\/journals\/research\/cell-host-microbe\/PDFs\/CHOM_2264_S50.pdf\">A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2<\/a><\/p>\n<p>By using MBLI\u2019s peptide screening MHC tetramer exchange QuickSwitch&#x2122; platform, you can identify\/validate the binding of predicted peptide sequences of the COVID-19 viral proteins in most common alleles: H2Kb, A2, A11, A24, A3 and DR1, DR4, DR15.<\/p>\n<p>We can help to evaluate hundreds of predicted peptides for their ability to sit in the groove of MHC Class I and II with answers to the following points of inquiry:<\/p>\n<p>1. Does your vaccine elicit T-cell responses in hosts?<\/p>\n<p>a. Validating peptide binding affinities to multiple MHC Class I and II alleles.<\/p>\n<p>b. MHC tetramers for assessing and monitoring immune responses to individual peptides.<\/p>\n<p>2. Information on immunogenic \/ protective peptides (vaccine design\/fine tuning)<\/p>\n<p>a. Identifying and validating promiscuous MHC class II epitopes.<\/p>\n<p>b.Testing modified peptides on anchoring amino acids for optimal MHC binding and T-cell activation.<\/p>\n<p>3. In addition, this platform can also be used in\u00a0<em>in vitro\u00a0<\/em>assays to identify immune-potentiating candidate agents for their ability to enhance vaccines potency.<\/p>\n<p>Please\u00a0<a href=\"mailto:techsupport@caltagmedsystems.co.uk\" rel=\" noopener\">contact us<\/a>\u00a0today for a personalized discussion to see how we can quickly help you gather accurate and relevant information for your research against COVID-19.<\/p>\n<h2>Related COVID-19 Posts<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.caltagmedsystems.co.uk\/information\/2019-ncov-antibodies-from-prosci\/\">2019-nCoV Antibodies from ProSci<\/a><\/li>\n<li><a href=\"https:\/\/www.caltagmedsystems.co.uk\/information\/covid-19-sars-cov-2-detection-kits\/\">COVID-19\/SARS-CoV-2 Detection Kits<\/a><\/li>\n<li><a href=\"https:\/\/www.caltagmedsystems.co.uk\/information\/interleukin-6-release-in-response-to-coronavirus-19\/\">Interleukin-6 release in response to Coronavirus 19<\/a><\/li>\n<li><a href=\"https:\/\/www.caltagmedsystems.co.uk\/information\/coronavirus-covid-19-research-tools\/\">Coronavirus (COVID-19) Research Tools<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>COVID-19 infected cells can be recognized by T-cells only after SARS-CoV-2 peptides are processed and presented in the context of self MHCs. Identifying these peptides have essential utilities: Immune monitoring: Using peptide-MHC tetramers to assess vaccine-induced immunity Designing potent vaccines<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[517,1,202,15],"tags":[516,515,226,224,130],"class_list":["post-5855","post","type-post","status-publish","format-standard","hentry","category-covid-19","category-general-information","category-infectious-disease","category-tetramer","tag-coronavirus","tag-covid-19","tag-peptide","tag-tetramer","tag-vaccines"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/5855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=5855"}],"version-history":[{"count":4,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/5855\/revisions"}],"predecessor-version":[{"id":5892,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/5855\/revisions\/5892"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=5855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=5855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=5855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}